Enabling you to identify and mitigate the intrinsic risk in your operations, supply chains and business processes.
Evaluating how your products and services meet and exceed quality, safety, sustainability and performance standards.
Validating the specifications, value and safety of your raw materials, products and assets.
Inhaled biologics present a highly attractive route for the administration of biologic therapeutics as they allow systemic and targeted delivery to the lung, particularly beneficial for the treatment of respiratory diseases, whilst avoiding gastrointestinal degradation. They encourage patient adherence as they are more convenient to use as compared to other routes of administration and it is forecasted that this product class will continue to increase in importance in the pharmaceutical market. In this presentation, which was delivered at the Inhalation and Respiratory Drug Products Conference, Chris Vernall, Business Development Director, Intertek Melbourn, discusses the challenges to overcome during the development of inhaled or nasal delivered biologic including formulation, characterization of the biologics, stability and performance testing of the drug product. Please complete the form to download the presentation.